These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20601370)

  • 1. Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer.
    Karachaliou N; Saloustros E; Vamvakas L; Mavroudis D; Georgoulias V
    Ann Oncol; 2010 Aug; 21(8):1729-1730. PubMed ID: 20601370
    [No Abstract]   [Full Text] [Related]  

  • 2. Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.
    Farhat MH; El-Saghir NS; Shamseddine AI
    Breast; 2009 Feb; 18(1):66-8. PubMed ID: 19013064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
    Miller K; Wang M; Gralow J; Dickler M; Cobleigh M; Perez EA; Shenkier T; Cella D; Davidson NE
    N Engl J Med; 2007 Dec; 357(26):2666-76. PubMed ID: 18160686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer.
    Miller KD
    Clin Breast Cancer; 2003 Feb; 3(6):421-2. PubMed ID: 12636887
    [No Abstract]   [Full Text] [Related]  

  • 5. Bevacizumab and breast cancer: the E2100 outlier.
    Fojo T; Wilkerson J
    Lancet Oncol; 2010 Dec; 11(12):1117-9. PubMed ID: 21126685
    [No Abstract]   [Full Text] [Related]  

  • 6. Integrative tumor board: metastatic breast cancer.
    Koch A; Ellis J; Gyllenhaal C; Tripathy D; Lo C; Oberbaum M; Samuels N; Singer SR; Gupta G; Block KI
    Integr Cancer Ther; 2006 Dec; 5(4):373-90. PubMed ID: 17183755
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment with weekly paclitaxel and carboplatin combined with trastuzumab in a patient with heavily pretreated metastatic breast cancer.
    Kikuchi Y; Takano M; Kudoh K; Kita T; Sato K
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):189-91. PubMed ID: 18778887
    [No Abstract]   [Full Text] [Related]  

  • 8. [A case of a patient with a triple negative breast cancer and complete response of lung, mediastinal and skeletal metastases after treatment with paclitaxel and bevacizumab].
    Bravencová Z
    Klin Onkol; 2010; 23(5):358-60. PubMed ID: 21061684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-angiogenic therapies in metastatic breast cancer-an unfulfilled dream.
    Buzdar AU
    Lancet Oncol; 2011 Apr; 12(4):316-8. PubMed ID: 21429798
    [No Abstract]   [Full Text] [Related]  

  • 10. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
    Yagi Y; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Fujita H; Ninomiya I; Fujimura T; Kayahara M; Kinuya S; Yashiro M; Hirakawa K; Ohta T
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):745-53. PubMed ID: 20033809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystoid macular edema without leakage secondary to nab-Paclitaxel (Abraxane): clinical experience with intravitreal bevacizumab.
    Rahman HT; Yeh S; Bergstrom CS
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):360-2. PubMed ID: 23061416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis of the jaw related to bevacizumab.
    Estilo CL; Fornier M; Farooki A; Carlson D; Bohle G; Huryn JM
    J Clin Oncol; 2008 Aug; 26(24):4037-8. PubMed ID: 18711196
    [No Abstract]   [Full Text] [Related]  

  • 13. Paclitaxel-induced remission in docetaxel-refractory anthracycline-pretreated metastatic breast cancer.
    Suzuma T; Sakurai T; Yoshimura G; Umemura T; Tamaki T; Naito Y
    Anticancer Drugs; 2000 Aug; 11(7):569-71. PubMed ID: 11036960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab.
    González Cao M; Viteri S; Garrán C; Nieto Y; Aristu J; Ponz M; Martín Algarra S
    Clin Transl Oncol; 2007 Feb; 9(2):119-20. PubMed ID: 17329225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grade 4 epistaxis in a woman with metastatic breast cancer treated with bevacizumab: a case report.
    Yanagihara K; Takei H; Iida S; Yamashita K; Kurita T; Iwamoto M; Saegusa H; Uchida E
    J Nippon Med Sch; 2014; 81(5):333-6. PubMed ID: 25391703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
    Coltelli L; Allegrini G; Orlandi P; Giuntini N; Alì G; Fioravanti A; Bona E; Barletta MT; Fontanini G; Del Tacca M; Danesi R; Falcone A; Bocci G
    Pharmacogenomics; 2009 Aug; 10(8):1225-9. PubMed ID: 19663667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
    Soria JC
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S35-6. PubMed ID: 16719155
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical significance and pathological evaluation of neoadjuvant chemotherapy in breast cancer].
    Chen LR
    Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):218-21. PubMed ID: 20654118
    [No Abstract]   [Full Text] [Related]  

  • 20. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
    Martin M; Roche H; Pinter T; Crown J; Kennedy MJ; Provencher L; Priou F; Eiermann W; Adrover E; Lang I; Ramos M; Latreille J; Jagiełło-Gruszfeld A; Pienkowski T; Alba E; Snyder R; Almel S; Rolski J; Munoz M; Moroose R; Hurvitz S; Baños A; Adewoye H; Hei YJ; Lindsay MA; Rupin M; Cabaribere D; Lemmerick Y; Mackey JR;
    Lancet Oncol; 2011 Apr; 12(4):369-76. PubMed ID: 21429799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.